These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 23100242)

  • 1. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: targets in sports drug testing.
    Thevis M; Möller I; Beuck S; Schänzer W
    Methods Mol Biol; 2013; 952():301-12. PubMed ID: 23100242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine.
    Sobolevsky T; Dikunets M; Sukhanova I; Virus E; Rodchenkov G
    Drug Test Anal; 2012 Oct; 4(10):754-60. PubMed ID: 22977012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Möller I; Schäfer M; Rodchenkov G; Yin S; Loo JA; Geyer H; Schänzer W
    Eur J Mass Spectrom (Chichester); 2010; 16(3):301-12. PubMed ID: 20530837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis.
    Trevisiol S; Moulard Y; Delcourt V; Jaubert M; Boyer S; Tendon S; Haryouli H; Taleb W; Caroff M; Chabot B; Drif L; André F; Garcia P; Loup B; Popot MA; Bailly-Chouriberry L
    Drug Test Anal; 2021 Jun; 13(6):1191-1202. PubMed ID: 33547737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs.
    Thevis M; Schänzer W
    Rapid Commun Mass Spectrom; 2016 Mar; 30(5):635-51. PubMed ID: 26842585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS.
    Kintz P; Ameline A; Gheddar L; Raul JS
    Drug Test Anal; 2020 Jul; 12(7):980-986. PubMed ID: 32298044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry for doping control.
    Ishii H; Shibuya M; Leung GN; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Mar; 35(5):e9028. PubMed ID: 33319421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doping control analysis of trimetazidine and characterization of major metabolites using mass spectrometric approaches.
    Sigmund G; Koch A; Orlovius AK; Guddat S; Thomas A; Schänzer W; Thevis M
    Drug Test Anal; 2014; 6(11-12):1197-205. PubMed ID: 24913825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism studies on the selective androgen receptor modulator (SARM) LG121071 and its implementation into human doping controls using liquid chromatography-mass spectrometry.
    Knoop A; Krug O; Vincenti M; Schänzer W; Thevis M
    Eur J Mass Spectrom (Chichester); 2015; 21(1):27-36. PubMed ID: 25906032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes.
    Höppner S; Delahaut P; Schänzer W; Thevis M
    J Pharm Biomed Anal; 2014 Jan; 88():649-59. PubMed ID: 24239904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra high performance liquid chromatography tandem mass spectrometry determination and profiling of prohibited steroids in human biological matrices. A review.
    Gosetti F; Mazzucco E; Gennaro MC; Marengo E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 927():22-36. PubMed ID: 23317577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting prohibited substances in doping control blood samples by means of chromatographic-mass spectrometric methods.
    Thevis M; Thomas A; Schänzer W
    Anal Bioanal Chem; 2013 Dec; 405(30):9655-67. PubMed ID: 23925796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioactivity screening and mass spectrometric confirmation for the detection of PPARδ agonists that increase type 1 muscle fibres.
    Bovee TF; Blokland M; Kersten S; Hamers AR; Heskamp HH; Essers ML; Nielen MW; van Ginkel LA
    Anal Bioanal Chem; 2014 Jan; 406(3):705-13. PubMed ID: 24287635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet.
    Thevis M; Geyer H; Thomas A; Schänzer W
    Drug Test Anal; 2011 May; 3(5):331-6. PubMed ID: 21538997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing.
    Thevis M; Lagojda A; Kuehne D; Thomas A; Dib J; Hansson A; Hedeland M; Bondesson U; Wigger T; Karst U; Schänzer W
    Rapid Commun Mass Spectrom; 2015 Jun; 29(11):991-9. PubMed ID: 26044265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary information concerning the suspected interindividual transmission of GW1516, a substance prohibited in sport, through intimate contact: a case report.
    Breuer J; Garzinsky AM; Thomas A; Nieschlag E; Kliesch S; Fedoruk M; Geyer H; Thevis M
    Forensic Toxicol; 2024 Jul; 42(2):248-254. PubMed ID: 38704758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and longitudinal distribution of GW1516 and its metabolites in equine hair for doping control using liquid chromatography/high-resolution mass spectrometry.
    Ishii H; Shibuya M; Leung GN; Nozawa S; Yamashita S; Yamada M; Kushiro A; Kasashima Y; Okada J; Kawasaki K; Kijima-Suda I
    Rapid Commun Mass Spectrom; 2021 Apr; 35(8):e9050. PubMed ID: 33470485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometric characterization of the hypoxia-inducible factor (HIF) stabilizer drug candidate BAY 85-3934 (molidustat) and its glucuronidated metabolite BAY-348, and their implementation into routine doping controls.
    Dib J; Mongongu C; Buisson C; Molina A; Schänzer W; Thuss U; Thevis M
    Drug Test Anal; 2017 Jan; 9(1):61-67. PubMed ID: 27346747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor δ (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).
    Pokrywka A; Cholbinski P; Kaliszewski P; Kowalczyk K; Konczak D; Zembron-Lacny A
    J Physiol Pharmacol; 2014 Aug; 65(4):469-76. PubMed ID: 25179079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.